Search Results
Search for other papers by Wen-xi Sun in
Google Scholar
PubMed
Search for other papers by Hao-nan Liu in
Google Scholar
PubMed
Search for other papers by Meng-tong Chen in
Google Scholar
PubMed
Search for other papers by Yong-peng Lin in
Google Scholar
PubMed
Search for other papers by Hong-shen Wang in
Google Scholar
PubMed
Division of Spine Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
Search for other papers by Bo-lai Chen in
Google Scholar
PubMed
Objective
-
The aim of this study was to comprehensively evaluate the efficacy of oblique lateral interbody fusion (OLIF) and transforaminal lumbar interbody fusion (TLIF) in the treatment of degenerative lumbar spondylolisthesis by meta-analysis.
Methods
-
A computer-based search of PubMed, Cochrane Library, Embase, Web of Science Core Collection databases, the China National Knowledge Infrastructure, China Biology Medicine, and Wanfang Digital Periodicals was conducted from the time of inception of each database to December 2021. The review process was conducted according to the PRISMA guidelines and registered in the PROSPERO database. Meta-analysis was performed using RevMan 5.4 software provided by the Cochrane Library.
Results
-
Thirteen studies were included in the statistical analysis. One randomized controlled study and 12 cohort studies with 954 patients were included. In terms of operation time, intraoperative blood loss, Oswestry disability index score, intervertebral height, and complications, the OLIF group was better than the TLIF group, and the difference was statistically significant (P < 0.05). There was no significant difference between the two groups in terms of visual analogue scale score, lumbar lordosis or fused segment lordosis (P > 0.05).
Conclusion
-
Both OLIF and TLIF are effective surgical modalities in the treatment of degenerative lumbar spondylolisthesis. They achieve similar therapeutic effects, but OLIF is superior to TLIF in restoring intervertebral height. At the same time, OLIF has the advantages of short operation time and less intraoperative blood loss.
Search for other papers by Wen-xi Sun in
Google Scholar
PubMed
Search for other papers by Wei-qiang Huang in
Google Scholar
PubMed
Search for other papers by Hua-yang Li in
Google Scholar
PubMed
Search for other papers by Hong-shen Wang in
Google Scholar
PubMed
Search for other papers by Sheng-li Guo in
Google Scholar
PubMed
Search for other papers by Jie Dong in
Google Scholar
PubMed
Search for other papers by Bo-lai Chen in
Google Scholar
PubMed
Search for other papers by Yong-peng Lin in
Google Scholar
PubMed
Purpose
-
To determine whether using robots in spine surgery results in more clinical advantages and fewer adverse consequences.
Methods
-
Between October 1990 and October 2022, a computer-based search was conducted through the databases of PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, China Biology Medicine, VIP databases, and WAN FANG. The study only included randomized controlled trials (RCTs) comparing the clinical efficacy and safety of robot-assisted surgery with those of conventional spine surgery. The review was conducted following PRISMA 2020, and AMSTAR-2 was used to evaluate the methodological quality. R version 4.2.1 was used in the meta-analysis. The Cochrane Collaboration Tool was used for evaluating the risk of bias.
Results
-
This study analyzed 954 participants from 20 RCTs involving cervical spondylosis, lumbar degenerative disease, scoliosis, etc. The robot-assisted group outperformed the freehand group in terms of intraoperative blood loss, number of screws in grade A position, grade A + B position, radiation dose, and hospital stay. Operation duration, visual analog scale scores of low back pain, Oswestry disability index, and radiation exposure time did not significantly differ between the two groups.
Conclusions
-
Although robotic spine surgery is more accurate in pedicle screw placement than conventional methods, the robot group did not demonstrate an advantage in terms of clinical efficacy. Studies of complications and cost-effectiveness are still very rare.